CIBSS in den Medien
Newly-developed inhibitor for prostate cancer demonstrates significant potential
In Germany, more than 65,000 men are diagnosed with prostate cancer each year, with 12,000 of them developing a treatment-resistant form that can lead to death. Researchers from the Medical Faculty at the University of Freiburg have developed a new active substance, KMI169, which targets an enzyme involved in the development of prostate cancer. This inhibitor has shown promise in combating resistant cancer cells.
vervetimes.comProstate cancer: Newly-developed inhibitor shows massive potential
More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option. This substance, known as KMI169, targets an enzyme that plays an important role in the development of prostate cancer. The inhibitor displayed massive potential in among others cancer cells that were resistant to conventional treatments.
newsconcerns.comObesity: EPAC1 protein that increases brown fat identified
Obesity: why brown fat matters
The long-term goal of the study is to find drugs that support weight loss. Obesity is defined as a pathological increase in white fat and has become a major problem worldwide, with a significantly increased risk of cardiovascular diseases such as heart attack and stroke.
pledgetimes.comRuxolitinib May Improve Control vs. Best Available Treatment in Steroid Refractory/Dependent cGVHD
After 3 years, ruxolitinib provided improved control for steroid refractory or dependent chronic graft-versus-host disease when compared with best available treatment.
oncnursingnews.comDecoding the Brain’s Code: New Research Promises to Revolutionize Neuroprosthetics
An interdisciplinary team of researchers at the University of Freiburg has unlocked significant findings on the functioning of the sensorimotor cortex. These discoveries hold the potential to revolutionize the development of neuroprosthetic devices, designed to interface with the nervous system and compensate for neuronal dysfunctions.
bnnbreaking.comNeue Landkarte des Immunsystems an Grenzregionen des Gehirns erstellt
Freiburger Forschende haben die zelluläre Zusammensetzung der Immunbarriere des Gehirns neu definiert. Die Studie ist im Fachmagazin “Nature Medicine” erschienen.
biermann-medizin.de/Neue Landkarte des Immunsystems an Grenzregionen des Gehirns erstellt
Das Gehirn ist durch mehrere Barrieren vor potenziell schädlichen Einflüssen der Außenwelt abgegrenzt. Forscher*innen der Medizinischen Fakultät der Universität Freiburg gelang die Erstellung eines neuartigen Immunzellatlas dieser Grenzzonen des Gehirns mittels neuester, hochauflösender Methoden zur Untersuchung von Einzelzellen.
innovations-report.deRuxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD
Treatment with ruxolitinib led to prolonged failure-free survival and improved disease control vs best available treatment in patients with either steroid-refractory or -dependent chronic graft-vs-host disease.
onclive.comWechselwirkungen von Partikeln an der Zelloberfläche
in Messtechnik, Trends der Woche by redaktion
lppro.felchner-medien.deKrebsimmuntherapie mit veränderten CAR-T-Zellen noch wirksamer machen
Freiburger Forschende erzielten im präklinischen Modell eine deutlich verbesserte Anti-Tumor-Wirkung von CAR-T-Zellen
dgfi.org